NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
Novartis
Eli Lilly and Company
Genentech, Inc.
Novartis
Thomas Jefferson University
Medical University of South Carolina